Olaparib""?

David J VanderWeele1, Maha Hussain1

  • 1Division of Hematology/Oncology, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago.

NEJM evidence
|February 6, 2024
PubMed
概括

聚氨酸二酸) 聚合酶 (PARP) 抑制剂在治疗转移性割抵抗性前列腺癌 (mCRPC) 中表现有前途. 将PARP抑制剂与雄激素受体抑制剂结合起来,可能会使更广泛的患者群体受益,尽管结果在不同研究中有所不同.